Directory of Peptide API Manufacturing Plants

Sinopep-Allsino Biopharmaceutical is a global commercial API provider and full-service CDMO focused on end-to-end CMC development and commercial production of peptides, oligonucleotides and small molecule APIs. Serving global innovative pharmaceutical companies since 2009, it has passed four US FDA inspections and strictly follows FDA and ich guidelines. The peptide production capacity reaches 20–30 metric tons per year; a large-scale GMP oligonucleotide base has been built in Lianyungang, Jiangsu Province (annual output can reach thousands of kilograms, containing ASO, siRNA, GalNAc, AOC, liposomes and other conjugates). Services cover polypeptide/oligonucleotide CDMO, FTE, discovery services, generic APIs and preparations (oral solid preparations, lyophilized powder injections, etc.), providing process development, analytical method development and validation, stability research, and IND/NDA regulatory support to achieve a seamless connection from early development to commercial supply.

Teide Pharmaceutical (Zhejiang) Co., Ltd. (stock code 03880.HK) is a contract research, development and production organization (CRDMO) specializing in polypeptides, providing full-cycle services from early discovery, pre-clinical, clinical development to commercial production. Headquartered in Hangzhou, China, it has commercial production bases and offices in China and the United States, and has been deeply engaged in the field of polypeptides for more than 20 years. Provides CRO (polypeptide new chemical molecular entity discovery synthesis) and CDMO (polypeptide CMC development and commercial production) services, and has extended to oligonucleotide CDMO since 2021. It has provided more than 1,000 customers worldwide with support for the synthesis, development, production and CMC declaration of polypeptides that meet the regulatory requirements of major markets around the world. The project covers more than 50 countries such as China, the United States, Japan, Europe, South Korea and Australia. Clients include large pharmaceutical companies, biotech companies, virtual pharmaceuticals and start-ups. The peptide biochemical tirpopeptide drug substance in the subsidiary has completed the US FDA DMF registration.

Founded in 2000, Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical Co., Ltd. is a high-tech enterprise and enterprise technology center in Jiangsu Province. The company's new industrial base has been completed and put into operation in Jiangsu Changshu New Material Industrial Park. It is planned to be built according to the high standards of the pharmaceutical industry at home and abroad, and is the core carrier for the integration of polypeptide and small molecule drug research and development and commercial production. Representative peptide/polypeptide preparation products include: cortisol ® terlipressin for injection, Amgas ® octreotide acetate injection, Anqi ® carbetocin injection, lidine ® thymus method for injection, etc. The base can meet the needs of capacity upgrades and business development, and provide reliable products and professional technology solutions for domestic and foreign pharmaceutical partners. (Note: Group subordinates contain a small amount of non-pharmaceutical sectors such as hotels, etc., which have been omitted.)

Conscientia Industrial is a core member of the Conscientia Group, headquartered in China, focusing on the R&D, manufacturing and global marketing of high-quality APIs (APIs), peptides, nutritional ingredients, cosmetic ingredients and fine chemicals. Its manufacturing facilities and products comply with international standards such as GMP and ISO, and its APIs strictly comply with USP, BP, EP, JP, KP, CP and other pharmacopoeial requirements. In the field of peptides, the company provides high-purity peptide synthesis and supply. The products cover hundreds of peptides such as α-Casozepine, AOD-9604, BPC-157, CJC-1295, GHK-Cu, GLP-1 (smectin, tilapopeptide, liraglutide, mazdopeptide, retalutide, etc.), beauty and scientific research peptides, all of which have been verified by HPLC with purity of 98% +. The supply is stable and supports rapid global shipments. It is positioned to provide peptides and raw materials for the global life science and chemical industries.

Sichuan Tongsheng Biomedical Co., Ltd. (founded in 2011, Deyang) is committed to providing key starting materials (KSM) and intermediates for polypeptide drugs and chemical drugs. The products cover the screening, small trials, pilot trials to commercial production services of key materials for clinical new drugs, including polypeptide drugs KSM, Fmoc-amino acids, unnatural amino acids, polypeptide side chains, short peptides, and small molecular drugs KSM, Boc-amino acids, amino acid derivatives, and heterocyclic pharmaceutical intermediates. The company has a number of 50-5000L reactor multi-functional production lines (grams to 100 tons), R&D team of 30 people (including 2 doctorate, 6 master's), QC/QA of nearly 30 people; currently planning to build about 65 acres of new base (including GMP workshop, three multi-functional workshop and peptide protection amino acid line workshop), has provided custom synthesis services for the world's leading pharmaceutical companies, CDMO and API companies.

Suzhou Nike Tai Biotechnology Co., Ltd. (Suzhou) is an innovative biotechnology enterprise focusing on innovative research and development and customized production of polypeptides. Relying on advanced synthetic technology platform and strict quality management system, it provides high-purity, high-quality polypeptide raw materials and integrated solutions from milligrams to kilograms in the fields of medicine, skin care and health. The main business covers peptides/cosmetic peptides/pharmaceutical peptides: the field of peptide raw materials provides bioactive peptides (scientific research, diagnostics, pharmaceutical intermediates); cosmetic peptides focus on active peptides such as anti-aging, repair, and firming; pharmaceutical peptides focus on research and development and process development of highly difficult pharmaceutical peptides, providing innovative drug and generic drug companies with one-stop CMC services from preclinical to commercialization. Equipped with a modern R&D center and GMP-compliant production facilities, we aim to be a reliable partner in the field of peptide technology.

Sichuan Pengting Technology Co., Ltd. (founded in 2021, Sichuan) is positioned as a core value creator in the global peptide industry chain, focusing on the research and development, customization and industrial-scale production of high-value APIs and cosmetic peptides. Integrated supply chain and 6,500 ㎡ co-production base, products cover metabolic APIs (Tirzepatide, Semaglutide, Retatrutide, etc.) and popular cosmetic raw materials (GHK-Cu blue copper peptide, Melanotan-II, etc.). With ISO/GMP dual certification, we can provide a full set of DMF, COA and MSDS documents. The R&D team includes 5 + PhDs, and has industrialized more than 100 effective raw materials. We support 50g trial orders to tonnage commercial supply, with a delivery period of 15–30 days. Customers cover biotechnology innovation pharmaceutical companies, CDMOs, cosmetic brands and scientific research institutions in North America, Europe and Asia.

Founded in 2018, it focuses on the European, American, Indian, and African markets, and supports Paypal, Western Union, and Bitcoin payments.

Shenzhen Han Yu Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, 300199, listed in 2011) is a national high-tech enterprise specializing in the R&D, production and sales of polypeptide drugs and small nucleic acids. Founded in 1998, it is an early listed polypeptide drug enterprise in China. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for innovative polypeptide drugs, and a national pilot technology platform for the preparation of polypeptide drugs. It has undertaken a number of national-level projects and won the second prize of the National Technology Invention Award. It has passed the GMP/cGMP certification in China, the United States, the European Union, Brazil, Australia, South Korea and other countries, and has four major production bases: Shenzhen Pingshan Preparation Base, Wuhan Peptide Featured API Base (through the China/United States/Australia GMP certification, which is being expanded), Gansu Chengji Pharmaceutical Intermediates Base, Yunnan Dali Industrial Hemp Base, etc., to open up the whole chain control from raw materials to drugs. The APIs are sold to 20 + countries and regions, and the preparations are sold to 90 + countries and regions. The polypeptide products include GLP-1 injections such as liraglutide, smeclutide, tirpotide, etc., atoxiban, etibapeptide, etc., and have CRDMO (custom R&D + custom production) capabilities. The monomer reactor capacity is 100L-10000L.

Shenzhen Jianxiang Biotechnology (JYMed/Jianyuan Pharmaceutical) is a CDMO enterprise specializing in polypeptides, providing polypeptide API R&D and GMP production from milligrams to tons. With 13 cGMP production lines and 85,000 L spps/LPPS reactor volumes, the Hubei base has an annual production capacity of 10 + tons and has passed FDA, NMPA, and EDQM inspections. Employees of 650 + are located in Shenzhen (7,000 ㎡ R&D center), Hubei (52,000 ㎡ API production base, OEB-5 isolation), and Shenzhen (formulation FDF base). Services cover custom synthesis, polypeptide API manufacturing (long chain, unnatural amino acids, conjugates), cosmetics/veterinary drugs/health peptides and CDMO, supporting 1 g R&D to 100 kg commercial batches. With 20 + years of experience in peptide chemistry and CDMO, we provide peptide intermediates, APIs and CDMO services to pharmaceutical companies worldwide.

Shanghai Bootech Biotechnology Co., Ltd. (registered as "Bootech" on the official website, and the user is recorded as "Botech") was founded in 2003 and is a technology company specializing in the synthesis of peptides and the sale of supporting reagents. The company relies on and absorbs international advanced technology, has advanced synthesis and purification equipment, and develops a complete set of peptide synthesis routes, which can provide peptide products of various sizes and requirements (mg to kg). Each polypeptide is accompanied by HPLC analysis and mass spectrometry identification report. Provided by a number of senior researchers/professors to provide process guidance, long-term cooperation with domestic and foreign pharmaceutical companies and scientific research institutions to provide high-quality peptides and peptide raw materials products at a price advantage.

Qingdao Sigma Chemical Co., Ltd.) mainly develops, manufactures and sells pharmaceutical raw materials, chemical intermediates, biochemicals, veterinary drugs and nutritional products, with synthetic capacity ranging from grams to tons, and provides custom synthesis and contract production (CMO). Peptides are one of its product lines. The official website lists GHRP-6, CJC-1295, Melanotan, HGH Frag 176-191, Ipamorelin, Hexarelin, PT-141 and other peptide raw materials, and claims to have a professional production quality control team, domestic and foreign warehousing and global shipping channels.

Founded in 2013, Nanjing Jetpeptide Biotechnology Co., Ltd. (Jetpeptide Biotechnology) is an enterprise that integrates R&D, development and production of polypeptide reagents. The company can synthesize thousands of polypeptides of different sequences at the same time. It is equipped with a professional production team and equipment. From raw material procurement to final testing, each process is strictly controlled. The synthesis data, purification methods, quality inspection and mass spectrometry reports, and storage methods of each polypeptide are recorded in detail. It can provide research users and large enterprises with peptide products ranging from milligrams to kilograms and with the highest purity of 99%. It has supplied tens of thousands of active peptides to thousands of research users around the world. The products cover the whole country and are exported to Europe, the United States, the Middle East, Hong Kong, Macao and Taiwan. Complex modification capabilities include methylation, polyphosphorylation, head-tail cyclization, a variety of fluorescent labels, and book-linked peptides, and have successfully synthesized long peptides with more than 120 amino acid residues. Establish long-term cooperation with thousands of scientific research institutes, institutions and enterprises at home and abroad (including Baekje Shenzhou, Oxford University, National Protein Research Center, etc.), with legal import and export qualifications.

Established in 2023, Hangzhou Beiputai Biopharmaceutical Co., Ltd. is a high-tech enterprise focusing on the R&D and sales of polypeptides and related derivatives. The company has established a polypeptide R&D center in the Overseas Student Entrepreneurship Park in Qiantang District, Hangzhou. It is equipped with several polypeptide R&D production lines and large-scale analytical equipment such as Agilent high-performance liquid chromatography and AB mass spectrometry. The R&D team has more than 10 years of polypeptide experience and can meet personalized customization. Products include GLP-1 polypeptides (Smeglutide, Tirpopeptide, Retalutide, etc.), small molecule mimetic peptides, radioimaging polypeptide precursors (RDC precursors, such as FAPI/PSMA/Oct), PDC polypeptides, polypeptide inhibitors (aldehyde peptides/FMK/CMK, etc.), luciferase substrates, glycopeptides, isotope-labeled peptides, macrocyclic polypeptides, maps complex antigen peptides, fluorescent labeled peptides, cell transmembrane peptides, etc. More than 100 mature polypeptides have been produced, with an annual output of more than 100 kg of polypeptides.

Seno Biotechnology is a "specialized specialty" and national high-tech enterprise focusing on the field of polypeptides. It was listed in 2021 and integrates R&D, production and sales. Its business covers polypeptide APIs, cosmetic active peptides, CDMO services and polypeptide preparations. It is a leader in the field of polypeptide APIs in China and has a full industrial chain capability from drug discovery to commercial production. The core team has more than 15 years of peptide synthesis research and practical experience. Peptide API production capacity of 1.5 tons, single batch production of up to kg, master more than 50 domestic and foreign marketed peptide production of large-scale key technologies, products covering the digestive system, immune system, anti-tumor, chronic hepatitis B, diabetes and obstetrics and other therapeutic areas, a variety of products have passed the multi-national certification.